Pirfenidone for Idiopathic Pulmonary Fibrosis

Affiliations

Comment

Traci N Adams et al. Am J Respir Crit Care Med. 2016.

. 2016 Aug 1;194(3):374-6.

doi: 10.1164/rccm.201602-0258RR.

¹ Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.

No abstract available

Comment on

Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts.
Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. Conte E, et al. Eur J Pharm Sci. 2014 Jul 16;58:13-9. doi: 10.1016/j.ejps.2014.02.014. Epub 2014 Mar 12. Eur J Pharm Sci. 2014. PMID: 24613900
All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis.
Ogura T, Azuma A, Inoue Y, Taniguchi H, Chida K, Bando M, Niimi Y, Kakutani S, Suga M, Sugiyama Y, Kudoh S, Nukiwa T. Ogura T, et al. Respir Investig. 2015 Sep;53(5):232-41. doi: 10.1016/j.resinv.2015.06.001. Epub 2015 Aug 17. Respir Investig. 2015. PMID: 26344613
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.
Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE Jr. Noble PW, et al. Eur Respir J. 2016 Jan;47(1):243-53. doi: 10.1183/13993003.00026-2015. Epub 2015 Dec 2. Eur Respir J. 2016. PMID: 26647432 Free PMC article.